Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4164.70 +1.4% SILVER 56.66 +1.4% COPPER 6.54 −1.8% OIL 95.54 +0.5% PALLADIUM 1136.00 +3.6% EVI 0.500 +0.0% ADZ 0.125 +0.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.245 +0.0% BAU 0.190 +0.0% TECT 1.66 +0.0% TOM 0.135 +0.0% FVL 0.900 +0.0% HART 0.195 +0.0% VLD 0.415 +0.0% TGOL 0.150 +0.0% TWR 0.170 +0.0% LAF 0.810 +0.0% SAO 0.050 +0.0% GOLD 4164.70 +1.4% SILVER 56.66 +1.4% COPPER 6.54 −1.8% OIL 95.54 +0.5% PALLADIUM 1136.00 +3.6% EVI 0.500 +0.0% ADZ 0.125 +0.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.245 +0.0% BAU 0.190 +0.0% TECT 1.66 +0.0% TOM 0.135 +0.0% FVL 0.900 +0.0% HART 0.195 +0.0% VLD 0.415 +0.0% TGOL 0.150 +0.0% TWR 0.170 +0.0% LAF 0.810 +0.0% SAO 0.050 +0.0%

Healthcare

Page 21
  1. May 11, 2026 · 09:01 · TTI · Routine −

    Thiogenesis Secures Runway with Dilutive Financing Amidst Clinical Progress

    Thiogenesis Announces Non-Brokered Private Placement

    01
  2. May 11, 2026 · 08:50 · PAIN

    /C O R R E C T I O N -- Vector Sciences & Therapeutics/

    /C O R R E C T I O N -- Vector Sciences & Therapeutics/

    02
  3. May 11, 2026 · 08:50 · PAIN · Material +

    Vector swaps $6M capex for a cGMP key, unlocking shelf-stable peptides and signaling a manufacturing-first game plan.

    Vector Science & Therapeutics Enters Three-Year Development and Manufacturing Agreement with MPP Group LLC

    03
  4. May 11, 2026 · 08:45 · MBIO · Routine +

    MindBio Pivots from Clinical Failure to AI Voice Analytics, But Dilution Risks Loom

    MindBio Develops Fatigue Prediction Model using Speech Analytics and AI

    04
  5. May 11, 2026 · 08:30 · MBIO · Routine +

    MindBio Pivots from Failed Psychedelic Trial to AI Safety Tech Amidst Cash Burn Concerns

    The Future of Intoxication Detection May Be in Your Voice

    05
  6. May 11, 2026 · 08:30 · SURE · Routine +

    SureNano Advances GLP-1 Pipeline Amidst Cash Burn Concerns

    The Next Generation of the GLP-1 Revolution Is Already Underway

    06
  7. May 11, 2026 · 07:31 · CHER · Routine +

    Cheelcare extends its booking streak as Companion reimbursement catalyst takes hold, but the Curio regulatory journey and thin balance sheet keep risk elevated.

    Cheelcare Reports Second Consecutive Month of Record Companion Bookings with April Bookings up 147% Year-over-Year and 38.5% Sequentially

    07
  8. May 11, 2026 · 07:30 · CTX · Routine +

    Crescita Shares Trade Near Buyout Price as Q1 EBITDA Turnaround Validates Deal Viability

    Crescita Reports First Quarter 2026 Results

    08
  9. May 11, 2026 · 07:00 · CNVI · Routine −

    Conavi Medical files for fresh equity offering as cash reserves dwindle ahead of U.S. Novasight launch, raising dilution fears amid a share price plumbing near all-time lows.

    Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

    09
  10. May 11, 2026 · 02:34 · 4565 · Routine +

    GPCR spin-out reels in $275M in biobucks and equity, keeping Asia rights and cash burn in check

    Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing

    10
  11. May 08, 2026 · 18:00 · ONCO · Routine −

    Onco-Innovations Shares Crumble on Dilution Fears Despite IND Progress

    Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology

    11
  12. May 08, 2026 · 17:00 · PHA · Material −

    Lenders Terminate Forbearance After Default, Premier Health Faces Uncertain Future as Strategic Review Continues

    Premier Health Announces Termination of Forbearance Agreements With Principal Lenders and the Continuance of Its Strategic Review Process

    12
  13. May 08, 2026 · 07:30 · EDT · Routine +

    Spectral Medical Advances PMA Submission While Cash Burn Rate Demands Immediate Capital Attention

    Spectral Medical Announces First Quarter 2026 Financial Results and Provides Corporate Update

    13
  14. May 08, 2026 · 06:30 · GUD · Material +

    Knight Therapeutics scores Brazilian approval for TAVALISSE just as record sales lift stock to all‑time high

    Knight Therapeutics Announces Regulatory Approval of TAVALISSE(TM) in Brazil

    14
← Newer Older →